CLAIM #36921 · Eli Lilly and Company (LLY) · 2024Q3 earnings call · Oct 30, 2024 · due Dec 31, 2024
“That effect will continue for sure for getting into the fourth quarter of the year that is including as part of our guidance.”
Lucas Montarce · CFO
In context
“ople longer-term forecasting at least amongst the sell-side approaching high 40s percent. And I believe some of your commentary suggested that perhaps that would not be where you would aim for. Can you just maybe clarify for us your view, your take on where you think the operating margin trajectory would go under your purview? Joe Fletcher: Well, Lucas, go ahead. Lucas Montarce: Yes. Sorry. Thank you, Chris, for your question and thank you for quoting me about this new ratio, the gross margin minus OpEx divided by revenue is quite a lengthy ratio. But just going to your question in the short run you see that we have grown our ratio in the last few quarters as we have been having this cycle of significant growth trajectory and we are starting to ramp up our investment both in SG&A and R&D. That effect will continue for sure for getting into the fourth quarter of the year that is including as part of our guidance. And what we expect to see moving into 2025, going into your question is we do expect to ramp up our demand generation activities in SG&A that will pay down into 2025, as well as we will scale our R&D. We talk about some of the assets on our portfolio that moves into Phase 2 and Phase 3 that will continue to play-out as we ramp-up those investments to drive long-term sustainable growth. So, I would expect that in the short term, we continue to see some operating margin expansion on this ratio. In long term, again, we will continue to expand and drive sustainable growth that will basically justify the investments that we do in SG&A and R&D. Joe Fletcher: Thanks, Lucas. Next question. Operator: The next question will be from Trung Huynh from UBS. Trung, your line is live. Trung Huynh: Hi, gu”
Verify independently
SEC filings for LLY ↗ · Claim quote is verbatim from the 2024Q3 earnings call.